A Novel Fusion of ALT-803 (Interleukin (IL)-15 Superagonist) with an Antibody Demonstrates Antigen-specific Antitumor Responses

Lignende værker

• Combination therapy of an IL-15 superagonist complex, ALT-803, and a tumor targeting monoclonal antibody promotes direct antitumor activity and protective vaccinal effect in a syngenic mouse melanoma model
  af: Chen, Xiaoyue, et al.
  Udgivet: (2015)
• Evaluation of the biological activities of the IL-15 superagonist complex, ALT-803, following intravenous versus subcutaneous administration in murine models
  af: Liu, Bai, et al.
  Udgivet: (2018)
• Therapeutic administration of IL-15 superagonist complex ALT-803 leads to long-term survival and durable antitumor immune response in a murine glioblastoma model
  af: Mathios, Dimitrios, et al.
  Udgivet: (2015)
• The IL-15-based superagonist ALT-803 promotes the antigen-independent conversion of memory CD8(+) T cells into innate-like effector cells with antitumor activity
  af: Wong, Hing C, et al.
  Udgivet: (2013)
• Enhanced efficacy of IL-15-based ALT-803 superagonist complex in combination with immune checkpoint inhibitors in hematologic and metastatic mouse tumor models
  af: Xu, Wenxin, et al.
  Udgivet: (2014)